Verisante is focused on effective commercialisation of its laser Raman spectroscopy (LRS) technology, initially through Aura, a skin cancer diagnostic probe with global regulatory approvals. Fast, accurate and versatile, Aura could succeed where others have struggled. Potential de novo 510(k) FDA clearance for Aura is a key near-term catalyst. Core also applies LRS to aid the diagnosis of internal cancers, particularly lung cancer, which offers longer-term potential. Our fair value for Verisante is C$45m (C$0.55/share), but a c C$5m financing requirement is an overhang.

Unlock the rest of this Article in 15 seconds

or Unlock with your email

Already have an account?
Login here